Regeneron Pharmaceuticals Inc/ US75886F1075 /
| 08.11.2024 22:00:00 | Diff. +3,9400 | Volumen | Geld00:04:31 | Brief00:04:31 | Marktkapitalisierung | Dividendenr. | KGV |
|---|---|---|---|---|---|---|---|
| 828,4200USD | +0,48% | 563.585 Umsatz: 272,09 Mio. |
828,5000Geld Vol: 100 | 855,0000Brief Vol: 100 | 91,03 Mrd.USD | - | 22,36 |
Aktiva
| 2016 US GAAP in Mio. USD |
2017 US GAAP in Mio. USD |
2018 US GAAP in Mio. USD |
2019 US GAAP in Mio. USD |
2020 US GAAP in Mio. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sachanlagen | 2.083,4210 | 2.358,6050 | 2.575,8000 | 2.890,4000 | 3.221,6000 | ||||||
| Immaterielle Vermögensgegenstände | - | - | - | - | - | ||||||
| Finanzanlagen | 864,2600 | 1.486,4940 | 1.755 | 3.256,8000 | 3.135,6000 | ||||||
| Anlagevermögen | 3.793,2780 | 4.429,2560 | 5.286,9000 | 7.116,1000 | 7.384,2000 | ||||||
| Vorräte | 399,3560 | 726,1380 | 1.151,2000 | 1.415,5000 | 1.916,6000 | ||||||
| Forderungen | 1.343,3680 | 1.538,6420 | 1.723,7000 | 2.100 | 3.111,5000 | ||||||
| Liquide Mitteln | 535,2030 | 812,7330 | 1.467,7000 | 1.617,8000 | 2.193,7000 | ||||||
| Umlaufvermögen | 3.180,1880 | 4.335,0300 | 6.447,6000 | 7.689,1000 | 9.779,1000 | ||||||
| Aktiva, gesamt | 6.973,4660 | 8.764,2860 | 11.734,5000 | 14.805,2000 | 17.163,3000 | ||||||
Passiva
| 2016 US GAAP in Mio. USD |
2017 US GAAP in Mio. USD |
2018 US GAAP in Mio. USD |
2019 US GAAP in Mio. USD |
2020 US GAAP in Mio. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Verbindlichkeiten aus Lieferungen und Leistungen | - | - | 218,2000 | 418,1000 | 475,5000 | ||||||
| Langfristige Schulden | 351,5690 | 703,4530 | 708,5000 | 713,9000 | 2.695,7000 | ||||||
| Verbindlichkeiten gegenüber Kreditinstituten | - | - | - | - | - | ||||||
| Rückstellungen | - | - | - | - | - | ||||||
| Verbindlichkeiten | 2.524,2210 | 2.620,2080 | 2.977,2000 | 3.715,5000 | 6.138 | ||||||
| Gezeichnetes Kapital | ,1080 | ,1100 | ,1000 | ,1000 | ,1000 | ||||||
| Eigenkapital | 4.449,2450 | 6.144,0780 | 8.757,3000 | 11.089,7000 | 11.025,3000 | ||||||
| Minderheitenanteile | - | - | - | - | - | ||||||
| Passiva, gesamt | 6.973,4660 | 8.764,2860 | 11.734,5000 | 14.805,2000 | 17.163,3000 | ||||||
Gewinn- und Verlustrechnung
| 2016 US GAAP in Mio. USD |
2017 US GAAP in Mio. USD |
2018 US GAAP in Mio. USD |
2019 US GAAP in Mio. USD |
2020 US GAAP in Mio. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 4.860,4270 | 5.872,2270 | 6.710,8000 | 7.863,4000 | 8.497,1000 | ||||||
| Abschreibungen (Gesamt) | - | - | - | - | - | ||||||
| Betriebsergebnis | 1.330,7410 | 2.079,5910 | 2.534,4000 | 2.209,8000 | 3.576,6000 | ||||||
| Zinsergebnis | -7,1950 | -25,1190 | -28,2000 | -30,2000 | -56,9000 | ||||||
| Ergebnis vor Steuern | 1.329,8150 | 2.078,5110 | 2.553,5000 | 2.429,1000 | 3.810,4000 | ||||||
| Ertragsteuern | -434,2930 | -880 | -109,1000 | -313,3000 | 297,2000 | ||||||
| Gewinnanteil Minderheitsgesellschafter | - | - | - | - | - | ||||||
| Konzernjahresüberschuss | 895,5220 | 1.198,5110 | 2.444,4000 | 2.115,8000 | 3.513,2000 | ||||||
Pro Aktie
Cash Flow
| 2016 US GAAP in Mio. USD |
2017 US GAAP in Mio. USD |
2018 US GAAP in Mio. USD |
2019 US GAAP in Mio. USD |
2020 US GAAP in Mio. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow aus laufender Geschäftstätigkeit | 1.473,3960 | 1.307,1120 | 2.195,1000 | 2.430 | 2.618,1000 | ||||||
| Cash Flow aus Investitionstätigkeit | -1.046,9040 | -1.005,1820 | -1.463 | -2.027,8000 | -70,6000 | ||||||
| Cash Flow aus Finanzierungstätigkeit | -700,3910 | -24,4000 | -77,1000 | -252,1000 | -1.970,5000 | ||||||
| Veränderung der liquiden Mittel | -273,8990 | 277,5300 | 655 | 150,1000 | 577 | ||||||
| Anzahl der Mitarbeiter | 5.400 | 6.200 | 7.400 | 8.100 | 9.123 | ||||||
